AnaptysBio initiated with a Buy at Guggenheim. Guggenheim analyst Yatin Suneja initiated AnaptysBio with a Buy rating and $135 price target, calling its lead asset, etokimab, a “a pipeline-in-a-product with blockbuster potential” given its potential for broad applicability across multiple atopic diseases.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.